SarcopeniaNCT07764172
Sarcopenia in Acute Ischemic Stroke
An observational study of Sarcopenia and Acute Stroke, run by University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) at 1 site in Russia.
Trial summary
The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Sarcopenia, Acute Stroke
- How many people
- 400 participants
- Where
- 1 siteRussia
- Study dates
- 1 Aug 2026to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Adult, Older adult
Study population: The study population comprises patients with acute ischemic stroke admitted within the first 72 hours after symptom onset.
Who may be able to join
- Age 50 years and older
- Acute ischemic stroke confirmed by CT or MRI
- Admission within the first 72 hours
- Written informed consent and availability of a contact telephone number for follow-up
Who cannot join
- TIA without a visible lesion on neuroimaging; bilateral hemiparesis
- Amputations or severe contractures that preclude anthropometric assessment
- Active cancer at stage IV or life expectancy of less than 3 months
- Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months
- Pregnancy; refusal to participate
- Discontinuation criteria (drop-out)
Show all 9Show fewer
- Discharge or death within the first 7 days
- Withdrawal of consent
- Transfer to another facility resulting in loss of contact
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"
Moscow, 115446
Naida Garabova, PhD, +79611080888, garabova-ni@rudn.ru
About this study
Official title: Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes
The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is:
Is the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality?
Participants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.
- Conditions
- Sarcopenia, Acute Stroke
- Keywords
- sarcopenia, acute stroke
- Medical subject headings
- Sarcopenia, Stroke
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Barthel Index for Activities of Daily Living at 14 days
Lower scores indicate increasing disability and a greater need for skilled care. Min - 0 ( < 20 - totally dependent), max - 100 ( > 80 - independent).
Measured: Baseline and 14 days
Change from Baseline in Modified Rankin scale at 90 days
Min - 0 (no disability), max - 6 (dead). A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.
Measured: Baseline and 90 days
Secondary outcomes (11)
Number of Participants with sarcopenia
Measured: Baseline
Change from Baseline in arm muscle mass at 14 and 28 days.
Mid-upper arm circumference: measured at the midpoint between the acromion and the olecranon with the arm relaxed (2 measurements) in cm. Arm muscle circumference and area are calculated using the Heymsfield formula.
Measured: Baseline, 14 and 28 days
Change from Baseline in calf circumference at 14 and 28 days
Calf circumference: measured in the seated position, with the knee at a right angle, at the widest part of the non-paretic calf, with the tape snug but without compression (2 measurements) in cm. Calf circumference below 34 cm in men and 33 cm in women is classified as reduced.
Measured: Baseline, 14 and 28 days
Change from Baseline in handgrip strength at 14 and 28 days.
Handgrip dynamometry: performed in the seated position with the elbow at a right angle; three trials on the non-paretic hand, with the mean value used for analysis. Handgrip strength of the non-paretic hand below 27 kg in men and 16 kg in women is classified as reduced.
Measured: Baseline, 14 and 28 days.
Correlations between anthropometric measures and ultrasound/CT parameters
Measured: Baseline, 14, 28, and 90 days
Change from Baseline in National Institutes of Health Stroke Scale (NIHSS) at 24 hours, 7 and 14 days.
Min - 0, max - 42. A higher score means a patients has more severe symptoms. Patients with a score of <4 are highly likely to have good clinical outcomes.
Measured: Baseline, 24 hours, 7 and 14 days.
Change from Baseline in Rivermead Mobility Index at 14 and 28 days.
Min - 0, max - 15. Higher scores indicate better mobility performance. A score of 0 indicates an inability to complete any of the 15 tasks.
Measured: Baseline, 14 and 28 days.
Mortality at 14 and 90 days
Mortality rate at 14 and 90 days
Measured: 14 and 90 days
Hospital length of stay
Days. Total number of days spent admitted to the hospital during the index hospital stay, calculated from admission date to final discharge date.
Measured: Up to 28 days
Intensive care unit length of stay
Days. Total number of days spent in the intensive care unit from the time of initial ICU admission to successful transfer or discharge to a step-down unit.
Measured: Up to 28 days
Number of Participants with recurrent events within 90 days
Measured: From baseline to 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2026
- Study start1 Aug 2026
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07764172
- Sponsor's protocol ID
- ACUTE-SARC-MC-2026
- Status last verified
- Jul 2026
- First submitted
- 4 Aug 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes
- ClinicalTrials.gov ID
- NCT07764172
- Acronym / sponsor ID
- ACUTE-SARC-MC-2026
- Conditions
- Sarcopenia, Acute Stroke
- Keywords
- sarcopenia, acute stroke
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)University, hospital or other
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 13 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is:
Is the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality?
Participants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study population comprises patients with acute ischemic stroke admitted within the first 72 hours after symptom onset.
Key inclusion criteria (4 listed)
- Age 50 years and older
- Acute ischemic stroke confirmed by CT or MRI
- Admission within the first 72 hours
- Written informed consent and availability of a contact telephone number for follow-up
Key exclusion criteria (9 listed)
- TIA without a visible lesion on neuroimaging; bilateral hemiparesis
- Amputations or severe contractures that preclude anthropometric assessment
- Active cancer at stage IV or life expectancy of less than 3 months
- Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months
- Pregnancy; refusal to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change from Baseline in Barthel Index for Activities of Daily Living at 14 days
Time frame: Baseline and 14 days
Lower scores indicate increasing disability and a greater need for skilled care. Min - 0 ( < 20 - totally dependent), max - 100 ( > 80 - independent).
Change from Baseline in Modified Rankin scale at 90 days
Time frame: Baseline and 90 days
Min - 0 (no disability), max - 6 (dead). A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.
11 secondary outcomes
Number of Participants with sarcopenia
Time frame: Baseline
Change from Baseline in arm muscle mass at 14 and 28 days.
Time frame: Baseline, 14 and 28 days
Change from Baseline in calf circumference at 14 and 28 days
Time frame: Baseline, 14 and 28 days
Change from Baseline in handgrip strength at 14 and 28 days.
Time frame: Baseline, 14 and 28 days.
Correlations between anthropometric measures and ultrasound/CT parameters
Time frame: Baseline, 14, 28, and 90 days
Change from Baseline in National Institutes of Health Stroke Scale (NIHSS) at 24 hours, 7 and 14 days.
Time frame: Baseline, 24 hours, 7 and 14 days.
Change from Baseline in Rivermead Mobility Index at 14 and 28 days.
Time frame: Baseline, 14 and 28 days.
Mortality at 14 and 90 days
Time frame: 14 and 90 days
Hospital length of stay
Time frame: Up to 28 days
Intensive care unit length of stay
Time frame: Up to 28 days
Number of Participants with recurrent events within 90 days
Time frame: From baseline to 90 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Sarcopenia
Recruiting
Muscle Deterioration in Hospitalized Cancer Patient
Oncologic Diseases
Enrolling by invitation
Physical Activity Interventions for Sleep Improvement and Sedative-Hypnotic Reduction in Middle-Aged and Older Adults: Investigating the Role of Sarcopenia
Insomnia Chronic, Hypnotics and Sedatives
RecruitingObservational study
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
Sarcopenia, Obesity
Not yet recruitingObservational study
Sarcopenia Risk in Obese T2DM Patients
Sarcopenia, Obesity Type 2 Diabetes Mellitus
Not yet recruiting
Creatine and Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation Plus Home-Based Exercise for Sarcopenia in Huntington's Disease
Huntington Disease, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"
Moscow, Russia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia and Acute Stroke, run by University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Barthel Index for Activities of Daily Living at 14 days (time frame: Baseline and 14 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.